Genomic Says New Studies Establish Oncotype DX's Prospective Outcomes Data

(RTTNews) - Genomic Health, Inc. (GHDX), a provider of genomic-based diagnostic tests, announced Monday that new studies establish Oncotype DX as the only genomic breast cancer test with prospective outcomes data in more than 5,700 patients to date, providing evidence that the biology information from the test should be included in treatment decisions.

In addition to the positive five-year results from a group of patients with low Oncotype DX Recurrence Score results from the watershed ECOG-ACRIN Cancer Research Group's TAILORx (Trial Assigning IndividuaLized Options for Treatment [Rx]) study, two additional positive international Oncotype DX clinical outcomes studies were presented at the 2015 European Cancer Congress or ECC2015, the company noted.

The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.

The company stated that two additional Oncotype DX clinical outcomes studies included positive results from a large, multi-center cohort from Clalit Health Services in Israel with follow-up exceeding 5 years, and a separate study of prospective survival results from the WSG Phase III Plan B trial in Germany.